# LUDI Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ludi-therapeutics

- Industry: Biotechnology
- Headquarters: Monaco, Monaco
- Website: www.luditherapeutics.com
- Latest round: Seed (May 25, 2021)
- Investors on record: 1

## About

LUDI Therapeutics is a biotechnology company focused on developing innovative therapeutic interventions aimed at addressing chronic diseases and unmet medical needs through cutting-edge solutions.Founded in 2020 by Cindy Benod, LUDI Therapeutics operates out of Monaco, Monaco. The company is dedicated to advancing therapeutic solutions and has made one deal as of May 25, 2021, when it raised seed funding to support its initiatives.LUDI THERAPEUTICS specializes in developing innovative biotechnology solutions aimed at advancing therapeutic interventions. The company focuses on creating a range of products designed to address complex health issues, particularly in the realms of chronic diseases and unmet medical needs. Their offerings are developed through rigorous research and are characterized by their methodologies intended to improve patient outcomes and enhance quality of life. The end-users of these therapeutics primarily include healthcare providers, hospitals, and clinics, who utilize these products to treat patients directly. LUDI THERAPEUTICS targets both domestic and international markets, with a specific emphasis on regions known for their advanced healthcare infrastructures, such as North America and Europe.LUDI THERAPEUTICS generates revenue through a multifaceted business model that includes direct sales to healthcare institutions and partnerships with pharmaceutical distributors. The company engages in B2B transactions, where healthcare providers acquire products through structured contracts or agreements, ensuring a steady supply of therapeutics to meet patient demands. Additionally, there may be subscription-based models for ongoing access to specific therapeutic solutions. Pricing structures for their flagship products reflect the extensive research and development invested in their creation, aligning with industry standards for biotechnology products. This revenue is essential for fostering continued innovation and expanding the company’s product portfolio.In May 2021, LUDI Therapeutics raised an undisclosed amount of seed funding led by Sport Horizon Holding S.p.a. The company will utilize this funding to address muscle injuries, part of its strategy to enhance its product offerings. Plans for future growth include the development of new therapeutic products and potential expansion into additional markets, particularly within Europe and North America, to leverage existing healthcare infrastructures. The investment from Sport Horizon Holding aims to support these initiatives and position LUDI Therapeutics for sustainable impacts in the healthcare sector.

## Funding rounds

- Seed, May 25, 2021 — Sport Horizon Holding

## Investors

- Sport Horizon Holding (https://capitalatlas.ai/funds/sport-horizon-holding) — Seed